May 02, 2024
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
May 01, 2024
Alkermes plc Reports First Quarter 2024 Financial Results
April 24, 2024
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
More than 200 Alkermes employees recently took time out of their normal work day to contribute their time and talents to a variety of local Massachusetts nonprofit organizations as part of our fifteenth Alkermes in Action employee volunteer day.
In celebration of International Women's Day, three senior female leaders at Alkermes reflected on their career journeys and their efforts to inspire inclusion.
Alkermes employees work with urgency -- in the laboratory, in the clinic and in the community -- seeking to make a meaningful difference for people living with complex and difficult-to-treat diseases. For many of our employees, this work is part of their personal mission to help patients, families and communities.
Olanzapine and samidorphan
Schizophrenia and Bipolar I Disorder (Pediatric)
Phase 3
Olanzapine and samidorphan is a once-daily, oral atypical antipsychotic drug approved for adults in the U.S.
Olanzapine and samidorphan is currently being evaluated for pediatric use in a phase 3 study. For more information about this study, please visit enlightenyouthstudy.com (U.S. audiences only) or clinicaltrials.gov/study/NCT05303064.
ALKS 2680
Narcolepsy Type 1
Phase 2
Narcolepsy Type 2
Phase 1
ALKS 2680 is an investigational, oral orexin 2 receptor agonist in development as a once-daily treatment for narcolepsy.
ALKS 2680 is currently being evaluated in the Vibrance-1 phase 2 study in adults with narcolepsy type 1. For more information about this study, please visit vibrancestudies.com (for U.S. audiences only) and clinicaltrials.gov/study/NCT06358950.
ALKS 2680 was previously evaluated in a phase 1 study in healthy volunteers, and in adults with narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia.
Orexin Agonists
Neuroscience Indications
Discovery
Additional orexin 2 receptor agonists are in discovery for excessive daytime sleepiness disorders and other neuropsychiatric disorders.